The discovery of genotype 16 as the prototype oncogenic human papillomavirus (HPV)
initiated a quarter century of laboratory and epidemiological studies that demonstrated their …

Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …

Vaccination has had a major impact on the control of infectious diseases. However, there
are still many infectious diseases for which the development of an effective vaccine has …

This paper attempts to summarize current knowledge about immune responses to vaccines
that correlate with protection. Although the immune system is redundant, almost all current …

Links between human papillomaviruses (HPVs) and cervical cancer were first suspected
almost 30 years ago. DNA of specific HPV types has since been found in almost all cervical …

Human papillomavirus (HPV) infection of the genital tract is common in young sexually
active individuals, the majority of whom clear the infection without overt clinical disease …

HPV L1 virus-like particle (VLP) vaccines administered in a prime/boost series of three
injections over six months have demonstrated remarkable prophylactic efficacy in clinical …

Background An estimated 15% of girls aged 9–14 years worldwide have been vaccinated
against human papillomavirus (HPV) with the recommended two-dose or three-dose …

Background An increase in worldwide HPV vaccination could be facilitated if fewer than
three doses of vaccine are as effective as three doses. We originally aimed to compare the …

Human papillomavirus (HPV) is causally associated with 5% of cancers, including cancers
of the cervix, penis, vulva, vagina, anus and oropharynx. The most carcinogenic HPV is HPV …